A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2014
At a glance
- Drugs NXN 462 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors NeurAxon
- 18 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.